Mark your calendars

Article

San Antonio Breast Cancer Symposium to Hold 33rd Annual SymposiumHIGHLIGHTS BREAKTHROUGHS IN RESEARCH AND TREATMENT

San Antonio Breast Cancer Symposium to Hold 33rd Annual Symposium
HIGHLIGHTS BREAKTHROUGHS IN RESEARCH AND TREATMENT



FOREMOST INTERNATIONAL BREAST CANCER SYMPOSIUM HIGHLIGHTS BREAKTHROUGHS IN RESEARCH AND TREATMENT

SAN ANTONIO, TEXAS, DEC. 8-12, 2010




What:
The 33rd CTRC-AACR San Antonio Breast Cancer Symposium will feature the latest findings in prevention, epidemiological, laboratory, translational and clinical breast cancer research. This year’s symposium will highlight new therapies in the pipeline, new approaches with existing agents and emerging biology that will affect the quest for personalized medicine.

To help you plan your coverage of the symposium, the program schedule is available at www.sabcs.org. An electronic press kit containing the press releases and highlighted abstracts will be available to subscribing reporters one week prior to the symposium via EurekAlert and Newswise, and by request through the AACR Communications Department.

This year’s CTRC-AACR San Antonio Breast Cancer Symposium will highlight:
• results of the AZURE trial, which will define the role of zolendronic acid;
• new data on the effect of obesity on risk and patient management;
• how clinicians might move beyond Herceptin in managing HER2 positive breast cancer;
• the role of circulating tumor cells in patient management and risk; and,
• mammography compliance data in the general population.

The CTRC-AACR San Antonio Breast Cancer Symposium attracts world leaders in cancer research and treatment, including clinical oncologists, basic scientists, translational researchers and epidemiologists, working to improve prevention, diagnosis and patient care with the ultimate goal of eradicating breast cancer.

When:
Dec. 8-12, 2010

Where:
Henry B. Gonzales Convention Center
San Antonio, Texas
 

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content